HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized prospective open-label single-arm clinical phase I trial
investigating dose finding, feasibility and safety of the combined treatment of HDM201 and
midostaurin in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3mut
applying an accelerated titration design.